(Reuters) – AstraZeneca (NASDAQ:AZN) stated on Tuesday it will purchase oncology business TeneoTwo Inc in a deal valued at up to $1.27 billion, including the company’s first-stage T-cell engager.
The London-listed drugmaker wants to buy all outstanding equity of TeneoTwo for an upfront payment of $100 million on deal closing.
